Kent William Mouw

This study identifies SLC25A28 as a synthetic lethal target in NER-deficient cancers, showing its loss impairs cell viability and increases oxidative stress.

The paper identifies an ERCC2 mutation-associated mutational signature in targeted panel sequencing data linked to nucleotide excision repair deficiency in bladder cancer and shows its clinical relevance.

This study identifies tumor-myeloid crosstalk as a driver of cisplatin resistance in bladder cancer and proposes PARP14 inhibition as a therapeutic strategy.

This study identifies KDM6 enzymes as targets of R2HG from mutant IDH, linking them to replication stress sensitivity in gliomas and introduces a DHODH inhibitor, GLIO-1, with potential clinical applications.

This study identifies TMEJ as the main repair pathway for APOBEC3A-induced DSBs and shows Polθ inhibition causes synthetic lethality in cancer cells with APOBEC3A activity.

The paper examines how platinum-based chemotherapy affects tumor immune microenvironments in urothelial cancer, finding that memory B cell infiltration correlates with improved survival in cisplatin-treated patients.

The paper predicts cancer cell-of-origin from DNA sequences by matching mutational landscapes to chromatin modification patterns in normal tissues.